98%
921
2 minutes
20
Human cytochrome P450 (CYP) enzymes in the brain represent a crucial frontier in neuroscience, with far-reaching implications for drug detoxification, cellular metabolism, and the progression of neurodegenerative diseases. The brain's complex architecture, composed of interconnected cell types and receptors, drives unique neuronal signaling pathways, modulates enzyme functions, and leads to distinct CYP gene expression and regulation patterns compared to the liver. Despite their relatively low levels of expression, brain CYPs exert significant influence on drug responses, neurotoxin susceptibility, behavior, and neurological disease risk. These enzymes are essential for maintaining brain homeostasis, mediating cholesterol turnover, and synthesizing and metabolizing neurochemicals, neurosteroids, and neurotransmitters. Moreover, they are key participants in oxidative stress responses, neuroprotection, and the regulation of inflammation. In addition to their roles in metabolizing psychotropic drugs, substances of abuse, and endogenous compounds, brain CYPs impact drug efficacy, safety, and resistance, underscoring their importance beyond traditional drug metabolism. Their involvement in critical physiological processes also links them to neuroprotection, with significant implications for the onset and progression of neurodegenerative diseases. Understanding the roles of cerebral CYP enzymes is vital for advancing neuroprotective strategies, personalizing treatments for brain disorders, and developing CNS-targeting therapeutics. This review explores the emerging roles of CYP enzymes, particularly those within the CYP1-3 and CYP46 families, highlighting their functional diversity and the pathological consequences of their dysregulation on neurological health. It also examines the potential of cerebral CYP-based biomarkers to improve the diagnosis and treatment of neurodegenerative disorders, offering new avenues for therapeutic innovation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932283 | PMC |
http://dx.doi.org/10.3390/jox15020044 | DOI Listing |
Pharmacotherapy
September 2025
Department of Biomedical Informatics, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear.
View Article and Find Full Text PDFClin Pharmacol Ther
September 2025
Molecular Brain Science Department, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Tanenbaum Centre for Pharmacogenetics, Toronto, Ontario, Canada.
Pharmacogenomics enables the personalization of drug therapy by linking genetic variations to differences in drug metabolism, efficacy, and risk of adverse reactions. Genetic polymorphisms within cytochrome P450 (CYP) genes significantly affect enzyme activity, influencing drug plasma levels, responses, and safety. Central to this process is accurate genotype-to-phenotype translation, especially for the CYP enzyme family, which metabolizes 70-80% of clinically used drugs.
View Article and Find Full Text PDFFish Shellfish Immunol
September 2025
Department of Marine Bio Food Science, Gangneung-Wonju National University, Gangneung, Gangwon 25457, Republic of Korea; KBIoRANCh Co.,Ltd, Gangneung, Gangwon 25457, Republic of Korea. Electronic address:
The most effective lipid mediators in inflammation are eicosanoids, which involve numerous enzymes such as cyclooxygenases (COX), lipoxygenases (LOX), and cytochrome P450 (CYP). Arctoscopus japonicus lipids (AJL) have been shown to inhibit inflammation, but their effects on cellular mechanisms via lipid mediators remain unclear. In this study, we examined the eicosanoid synthesis pathways for the anti-inflammatory effects of AJL in lipopolysaccharide (LPS)-stimulated RAW264.
View Article and Find Full Text PDFToxicol Ind Health
September 2025
Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Biruni University, İstanbul, Türkiye.
Neonicotinoid insecticides and triazole fungicides are widely used in agriculture, often in combination with other pesticides, leading to concerns about potential health effects. This study investigated the combined effect of these chemicals using the Comparative Toxicogenomics Database (CTD) to identify common target genes, followed by functional enrichment analysis and gene-gene and protein-protein interaction assessments. In this study, it was determined that pesticides may interfere with biological processes such as steroid hydroxylase activity, oxidoreductase activity, and steroid metabolism, and cause hormonal imbalances and endocrine system disorders.
View Article and Find Full Text PDFDrug Metab Dispos
July 2025
Collaborations Pharmaceuticals, Inc, Raleigh, North Carolina. Electronic address:
Cytochrome P450 (P450)-mediated drug-drug interactions (DDIs) are responsible for most adverse drug interactions, and occur when 2 concurrently administered drugs inhibit, upregulate, or are substrates of the same target enzyme. A machine learning approach enables the detection of DDIs with rarely used drugs, as well as newly approved drugs. To facilitate this, we present a framework for predicting DDIs by first predicting P450 interactions for both drugs, generating a fingerprint based on the predictions in addition to the molecular structures of the drugs, and training a machine learning model to predict the overall interaction.
View Article and Find Full Text PDF